Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
World J Gastroenterol ; 22(14): 3875-8, 2016 Apr 14.
Article in English | MEDLINE | ID: mdl-27076774

ABSTRACT

Gastrointestinal complications are a frequent cause of morbidity after transplantation and may affect up to 40% of kidney transplant recipients. Here we report a rare case of idiopathic giant esophageal ulcer in a kidney transplant recipient. A 37-year-old female presented with a one-week history of odynophagia and weight loss. Upon admission, the patient presented cold sores, and a quantitative cytomegalovirus polymerase chain reaction was positive (10(5) copies/mL). An upper endoscopy demonstrated the presence of a giant ulcer. Serological test and tissue biopsies were unable to demonstrate an infectious origin of the ulcer. Immunosuppression was reduced and everolimus was introduced. An empirical i.v. therapy with acyclovir was started, resulting in a dramatic improvement in symptoms and complete healing of the ulcer. Only two cases of idiopathic giant esophageal ulcer in kidney transplant recipients have been reported in the literature; in both cases, steroid therapy was successful without recurrence of symptoms or endoscopic findings. However, this report suggests that correction of immune imbalance is mandatory to treat such a rare complication.


Subject(s)
Deglutition Disorders/immunology , Esophageal Diseases/immunology , Immunocompromised Host , Immunosuppressive Agents/adverse effects , Kidney Transplantation/adverse effects , Ulcer/immunology , Adult , Antiviral Agents/therapeutic use , Biopsy , Deglutition Disorders/diagnosis , Deglutition Disorders/drug therapy , Drug Substitution , Drug Therapy, Combination , Esophageal Diseases/diagnosis , Esophageal Diseases/drug therapy , Esophagoscopy , Everolimus/administration & dosage , Female , Humans , Immunosuppressive Agents/administration & dosage , Treatment Outcome , Ulcer/diagnosis , Ulcer/drug therapy , Weight Loss , Wound Healing
2.
Menopause ; 23(1): 47-54, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26079974

ABSTRACT

OBJECTIVE: This study aims to evaluate the sexual function and quality of life (QoL) of naturally postmenopausal women affected by genitourinary syndrome of menopause who were treated with an ultralow-concentration estriol vaginal gel (0.005%). METHODS: Postmenopausal women with vulvovaginal atrophy symptoms and sexual disorders were enrolled in a case-control study. Women were treated with vaginal gel (containing 50 µg of estriol) daily for 3 weeks and then twice weekly up to 12 weeks. Determination of vaginal maturation index, evaluation of vaginal pH, and assessment of vaginal atrophy symptoms were carried out. QoL, sexual function, and distress were investigated using the Short Form 36, Female Sexual Function Index, and Female Sexual Distress Scale questionnaires. Changes between baseline and week 12 were assessed. RESULTS: Sixty-eight women were included in the study group, and 42 women were included in the control group. Women on estriol vaginal gel had a significant increase in vaginal maturation index and improvement of vaginal pH compared with baseline (P < 0.05). Mean total Female Sexual Function Index score improved, and Female Sexual Distress Scale score decreased from baseline to follow-up. Results from the Short Form 36 questionnaire showed a significant improvement in the overall index of somatic aspects (P < 0.05). The control group showed no changes from baseline evaluation (P = NS). CONCLUSIONS: Estriol vaginal gel (0.005%) therapy significantly improves the trophism of the vaginal mucosa and the sexual health and QoL of naturally postmenopausal women. These results confirm that low doses of vaginal estrogen must be considered as the first choice for the initial treatment of postmenopausal genitourinary symptoms.


Subject(s)
Estriol/administration & dosage , Postmenopause/psychology , Quality of Life , Sexual Dysfunction, Physiological/drug therapy , Vaginal Diseases/drug therapy , Administration, Intravaginal , Atrophy , Case-Control Studies , Female , Humans , Middle Aged , Sexual Behavior/drug effects , Sexual Behavior/psychology , Sexual Dysfunction, Physiological/etiology , Sexual Dysfunction, Physiological/psychology , Surveys and Questionnaires , Vagina/pathology , Vaginal Creams, Foams, and Jellies/administration & dosage , Vaginal Diseases/etiology , Vaginal Diseases/pathology , Vulva/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...